Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

PURPOSE: The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study of lenvat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Finn, Richard S., Ikeda, Masafumi, Zhu, Andrew X., Sung, Max W., Baron, Ari D., Kudo, Masatoshi, Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Mamontov, Konstantin, Meyer, Tim, Kubota, Tomoki, Dutcus, Corina E., Saito, Kenichi, Siegel, Abby B., Dubrovsky, Leonid, Mody, Kalgi, Llovet, Josep M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2020
Pynciau:
RAPID COMMUNICATIONS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7479760/
https://ncbi.nlm.nih.gov/pubmed/32716739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00808
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg